Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial

NARecruitingINTERVENTIONAL
Enrollment

45,257

Participants

Timeline

Start Date

January 30, 2024

Primary Completion Date

October 30, 2026

Study Completion Date

July 7, 2027

Conditions
DementiaCognitive ImpairmentCognitive DeclineAlzheimer Disease
Interventions
DIAGNOSTIC_TEST

MyCog

MyCog uses well-validated, self-administered, iPad-based measures from the NIH Toolbox for the Assessment of Neurological Behavior and Function Cognition Battery to provide an efficient and sensitive cognitive screen that can be easily implemented in primary care. Preliminary data shows these tests can discriminate between cognitively normal older adults and those with CI (specifically mild cognitive impairment); enabling physicians to assess CI in ways currently not available.

Trial Locations (1)

60617

RECRUITING

Oak Street Health, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Oak Street Health

UNKNOWN

collaborator

University of Illinois at Chicago

OTHER

lead

Northwestern University

OTHER

NCT05607732 - Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial | Biotech Hunter | Biotech Hunter